Viking Therapeutics, Inc. in 2 stories
The narratives VKTX currently appears in, with its side and exposure in each.
Bull side
2 stories- GLP-1 Eats Everything
VKTX in “GLP-1 Eats Everything”
FadingExposure: not rated yetAppetite suppression as a macro variable.
Viking's injectable and oral obesity programs make it a high-beta challenger and potential acquisition target in metabolic medicine.
- The Patent Cliff Sparks a Biotech Land Grab
VKTX in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Positive obesity and metabolic-disease data give Viking scarce optionality in a category where established drugmakers are competing aggressively for pipelines.
Bear side
0 storiesNo bear-side stories for VKTX yet.